| |
|
|
Session 48
Poster Presentations Vaccine Adjuvants Tuesday 1:30 - 3:30 pm Hall D |
| 396 | Adjuvant Effects of an NKT Ligand, Y. Huang*1, Z. Chen1, W. Zhang1, Y. Song1, D. Gurner1, D. Gardiner1, A. Chen2, M. Tsuji1,2, D. D. Ho1 1Aaron Diamond AIDS Res Ctr, Rockefeller Univ, New York, NY and 2New York Univ |
| 397 | CTLA4-mediated APC Targeting Enhanced the Humoral and Cellular Immune Responses of an SIV DNA Vaccine in Mice W. Zhang*, Z. Chen, Y. Huang, Y. Song, D. D. Ho Aaron Diamond AIDS Res Ctr, Rockefeller Univ, New York, NY |
| 398 | CpG Stimulation of Interferon- J. C. Kuruppu*, K. Lore, R. W. Ross, R. A. Seder, R. A. Koup Vaccine Res Ctr, NIH, Bethesda, MD |
| 399 | IL-15 Enhances both Prophylactic and Immunotherapeutic Vaccines When Used in Combination with HIV-1 DNA Vaccines D. B. Weiner*1, M. Kutzler1, T. Robinson1, M. Lewis2, R. R. MacGregor3, J. D. Boyer1 1Univ of Pennsylvania, Philadelphia; 2Southern Res Inst, Frederick, MD; and 3Hosp of Univ of Pennsylvania, Philadelphia |
| 400 | Enhancement of Immune Responses to HIV-1 by DNA Vaccination Using the Complement Protein, C3d T. Ross*1, T. Green1, J. Sodroski2, J. Bower1 1East Carolina Univ, Sch of Med, Greenville, NC and 2Dana-Farber Cancer Inst, Boston, MA |
| 400a | Safe and Effective Use of CpG as Adjuvant for HBV Vaccination in HIV Infection CL Cooper*1, HL Davis2, ML Morris2, I Seguin1, JB Angel1, SM Elfer2, DW Cameron1 1Univ of Ottawa at the Ottawa Hosp, Ottawa, Ontario, Canada and 2Coley Pharmaceutical Group, Wellesley, MA |